Table 3 Multivariate analysis of locoregional recurrence-free survival (LRFS), relapse-free survival (RFS), and overall survival (OS) in patients with (i) T2-3N0M0 and (ii) T2-3N1-2M0 stage disease.

From: Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma

Factor   LRFS RFS OS
HR (95% CI) * p HR (95% CI) * p HR (95% CI) * p
(i) T2-3N0M0
T classification T2 1.000   1.000   
T3 13.341 (4.098–43.433) 0.001 8.351 (3.204–21.763) <0.001
Vascular invasion No    1.000  
Yes 5.703 (1.964–16.561) 0.001
Perineural invasion No    1.000  
Yes 3.398 (1.308–8.825) 0.012
(ii) T2-3N1-2M0
N classification N1 1.000   1.000   1.000  
N2 3.232 (1.591–6.566) 0.001 2.621 (1.388–4.948) 0.003 2.232 (1.218–4.091) 0.009
Postop CA 19-9 level ≤37 1.000   1.000   1.000  
(U/mL) >37 4.167 (1.929–9.001) 0.001 4.776 (2.366–9.641) <0.001 2.248 (1.215–4.160) 0.016
Vascular invasion No   1.000   1.000  
Yes 3.258 (1.384–7.668) 0.007 2.953 (1.620–5.383) <0.001
Lymphatic invasion No 1.000    
Yes 5.819 (1.801–18.798) 0.003
Adjuvant Therapy No-AT 1.000   1.000   1.000  
CTx 0.360 (0.170–0.760) 0.007 0.409 (0.203–0.826) 0.013 0.328 (0.165–0.651) 0.001
CRT 0.081 (0.029–0.228) <0.001 0.247 (0.123–0.497) <0.001 0.130 (0.060–0.282) <0.001
  1. Abbreviations: HR, hazard ratio; CI, confidence interval; others are the same as in Table 1.
  2. *Multivariate analysis using the Cox proportional hazards model.